Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

Example Evidence: MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

Generated Narrative: Evidence 236984

version: 69; Last updated: 2025-03-20 18:40:09+0000

Profile: ComparativeEvidence

RelatesTo

  • type: part-of
  • targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

url: https://fevir.net/resources/Evidence/236984

identifier: FEvIR Object Identifier/https://fevir.net/FOI/236984, outcomeId/109587, picoId/85798, sectionId/73215

name: Health_related_quality_of_life_from_MAGICapp_109587

title: MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

author: Computable Publishing®: MAGIC-to-FEvIR Converter:

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence CommunicationComparativeEvidence

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

assertion:

There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.

variableDefinition

description:

Adults with type 2 diabetes

variableRole: Population

observed: Adults with type 2 diabetes and CVD and CKD

variableDefinition

description:

GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

variableRole: Exposure

comparatorCategory: GLP-1 RA

observed: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

variableDefinition

description:

Health-related quality of life

variableRole: Outcome

observed: Health-related quality of life

synthesisType: SYSTEMATIC_REVIEW

studyDesign: NOTSET

statistic

description:

SMD 0.01 (CI95 -0.19 to 0.2 )

statisticType: Standardized Mean Difference

quantity: 0.01

AttributeEstimates

-TypeRange
*CI95-0.19-0.2

certainty

description:

Due to very serious imprecision

type: Overall certainty

rating: Low certainty

Subcomponents

-TypeRating
*Risk of BiasNOTSET
*InconsistencyNOTSET
*IndirectnessNOTSET
*ImprecisionVERY_SERIOUS
*Publication BiasNOTSET